ACHN Share Price

Open 4.21 Change Price %
High 4.34 1 Day 0.01 0.23
Low 4.19 1 Week 0.52 13.83
Close 4.28 1 Month 0.27 6.73
Volume 1637202 1 Year -3.44 -44.56
52 Week High 9.95
52 Week Low 3.71
ACHN Important Levels
Resistance 2 4.42
Resistance 1 4.36
Pivot 4.27
Support 1 4.20
Support 2 4.14
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
FTR 2.13 5.45%
FTR 2.13 5.45%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
LULU 50.76 -23.44%
More..
NASDAQ USA Top Gainers Stocks
CPSL 0.10 100.00%
LOCM 0.09 50.00%
QKLS 0.15 50.00%
PRAN 3.40 37.10%
ATHX 1.90 31.94%
ORIG 0.30 30.43%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
RITT 0.01 -50.00%
VALV 0.02 -50.00%
AMCF 0.05 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)

ACHN Technical Analysis 2
As on 30th Mar 2017 ACHN Share Price closed @ 4.28 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 6.53 & Buy for SHORT-TERM with Stoploss of 4.13 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACHN Target for March
1st Target up-side 4.55
2nd Target up-side 4.93
3rd Target up-side 5.31
1st Target down-side 3.47
2nd Target down-side 3.09
3rd Target down-side 2.71
ACHN Other Details
Segment EQ
Market Capital 720848960.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.achillion.com
ACHN Address
ACHN
300 George Street
New Haven, CT 06511
United States
Phone: 203-724-6000
Fax: 203-624-7003
ACHN Latest News
Interactive Technical Analysis Chart Achillion Pharmaceuticals, Inc. ( ACHN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Achillion Pharmaceuticals, Inc.
ACHN Business Profile
Achillion Pharmaceuticals, Inc., incorporated on August 17, 1998, is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.